|Bid||0.00 x 1000|
|Ask||0.00 x 1000|
|Day's Range||38.34 - 38.89|
|52 Week Range||24.80 - 47.69|
|PE Ratio (TTM)||N/A|
|YTD Daily Total Return||-0.90%|
|Beta (5Y Monthly)||0.63|
|Expense Ratio (net)||0.65%|
Pharmaceutical exchange-traded funds (ETFs) offer investors access to a basket of U.S.-based and foreign stocks of drug manufacturers and related companies in a single investment. These companies discover, develop, and produce medications used to cure disease, vaccinate, or alleviate symptoms of illness.
Emerging markets have been hit hard by coronavirus, but some were hit harder than others.
KraneShares, a global asset management firm known for its China-focused exchange-traded funds (ETFs) and innovative China investment strategies, today announced the launch of the Krane All China Growth Strategy. The model seeks to provide investors exposure to the brightest high-growth areas within China's economy. Specifically, the model will include China's rapidly growing internet and healthcare sectors, as well as the exact Mainland China A-Share securities being added into MSCI's Emerging Markets Index, tracked by $1.5 trillion in assets.1